NASDAQ:CNSP

Cns Pharmaceuticals Stock Insider Trading

etoro logo Buy CNSP
*Your capital is at risk
$6.70
-0.200 (-2.90%)
At Close: Nov 17, 2025

CNS Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 3.88M and sold 20K CNSP shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 3.88M shares
Sell 20K shares
96% Buy Activity
Strong Negative Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Jul 30, 2024
Buy
Common Stock
J-Other
Cortice Biosciences, Inc.
Insider
Other 0
Value: $0
Jul 30, 2024
Buy
Common Stock
J-Other
Cortice Biosciences, Inc.
Insider
Other 0
Value: $0
Jul 29, 2024
Buy
Common Stock
Cortice Biosciences, Inc.
10 Percent Owner
10% Owner 0
Value: $0
Jul 29, 2024
Buy
Common Stock
Cortice Biosciences, Inc.
10 Percent Owner
10% Owner 0
Value: $0
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Keyes Jeffry R.
Director
Director 17 500
Value: $9.80M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Keyes Jeffry R.
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Gumulka Jerzy
Director
Director 17 500
Value: $9.80M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Gumulka Jerzy
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Evans Carl Anthony
Director
Director 17 500
Value: $9.80M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Evans Carl Anthony
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Downs Christopher
Chief Financial Officer
C-Suite Officer 40 000
Value: $22.4M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Downs Christopher
Chief Financial Officer
C-Suite Officer 40 000
Value: $10.3K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Cockroft Bettina M.
Director
Director 17 500
Value: $9.80M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Cockroft Bettina M.
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Climaco John M
Chief Executive Officer
CEO / President 83 000
Value: $46.5M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Climaco John M
Chief Executive Officer
CEO / President 83 000
Value: $21.5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Charles Faith L.
Director
Director 17 500
Value: $9.80M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Charles Faith L.
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Charles Faith L.
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Charles Faith L.
Director
Director 17 500
Value: $9.80M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Climaco John M
Chief Executive Officer
CEO / President 83 000
Value: $21.5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Climaco John M
Chief Executive Officer
CEO / President 83 000
Value: $46.5M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Cockroft Bettina M.
Director
Director 17 500
Value: $5K
Apr 08, 2024
Buy
Restricted Stock Units
A-Award
Cockroft Bettina M.
Director
Director 17 500
Value: $9.80M
Apr 08, 2024
Buy
Option to purchase common stock
A-Award
Downs Christopher
Chief Financial Officer
C-Suite Officer 40 000
Value: $10.3K

About Insider Power

Insider Power is a proprietary algorithm developed by Stockinvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT CNS PHARMACEUTICALS, INC.
CNS Pharmaceuticals
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson...
GOLDEN STAR
Ticker Change Signal Date
UNIT
$6.00
4.83% Nov 04
TBPH
$14.14
27.58% Oct 23
A
AMIX
$1.12
2.68% Oct 23
COCO
$40.85
11.21% Oct 23
LAUR
$29.55
1.20% Oct 22

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE